Tiziana Life Sciences Ltd (TLSA) Cash Flow Statement
Where TLSA’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$12.8M
- Capital expenditures
- $21,000
- Free cash flow
- −$12.9M
- Returned to shareholders
- —
- Change in cash
- $286,000 cash at year-end $4.0M
Drawn to scale: where the cash came from and how it was used. Hover for values.
TLSA operating cash flow, capex and free cash flow
TLSA cash flow trends, 2023–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$12.4M2023 | −$12.8M2025 | — | |
| Capital expenditures | $02023 | $21,0002025 | — | |
| Free cash flow | −$12.4M2023 | −$12.9M2025 | — | |
| Stock-based compensation | $1.7M2023 | $1.1M2025 | −18.9%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
TLSA cash flow by activity
TLSA net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
TLSA cash flow statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating activities | |||
| Net income | −$18.4M | −$9.5M | −$14.0M |
| Depreciation & amortization | $234,000 | $124,000 | $96,000 |
| Stock-based compensation | $1.1M | $1.4M | $1.7M |
| Change in working capital | $3.1M | −$441,097 | −$1.3M |
| Other non-cash items | $1.1M | $7.1M | $999,091 |
| Cash from operating activities | −$12.8M | −$1.2M | −$12.4M |
| Investing activities | |||
| Capital expenditures | −$21,000 | −$15,181 | $0 |
| Investments (net) | $3.1M | −$71,000 | −$1.3M |
| Acquisitions & other investing | $0 | $29,446 | $261,434 |
| Cash from investing activities | $3.0M | −$56,735 | −$991,566 |
| Financing activities | |||
| Net borrowing (repayment) | −$196,000 | −$141,000 | −$119,000 |
| Shares issued | $10.1M | $4.6M | $24,000 |
| Other financing | $143,000 | −$830,100 | $126,654 |
| Cash from financing activities | $10.0M | $3.6M | $31,654 |
| Summary | |||
| Net change in cash | $286,000 | $2.0M | −$13.4M |
| Cash at end of period | $4.0M | $3.0M | $936,172 |
| Free cash flow | −$12.9M | −$1.2M | −$12.4M |
| Mar '26 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$12.8M | −$5.6M | −$5.6M | −$7.2M | −$5.8M | −$3.7M | −$3.7M | −$9.1M | −$7.2M | −$6.8M | −$6.8M | −$10.9M |
| Depreciation & amortization | $146,000 | $88,000 | $88,000 | $61,000 | $61,000 | $63,000 | $49,770 | $41,000 | $41,000 | $55,000 | $43,419 | $46,000 |
| Stock-based compensation | — | — | — | — | $1.4M | — | — | — | — | — | $1.7M | — |
| Change in working capital | $4.8M | −$1.7M | −$1.7M | −$2.2M | −$1.8M | $1.3M | $1.3M | $3.6M | $2.9M | −$4.1M | −$4.1M | $656,000 |
| Other non-cash items | $1.9M | $417,000 | $417,000 | $7.5M | $4.5M | $2.6M | $2.6M | $1.1M | $878,554 | $1.8M | $127,499 | $2.5M |
| Cash from operating activities | −$6.0M | −$6.8M | −$6.8M | −$1.9M | −$1.5M | $316,004 | $316,004 | −$4.3M | −$3.4M | −$9.0M | −$9.0M | −$7.7M |
| Investing activities | ||||||||||||
| Capital expenditures | −$15,000 | −$5,999 | −$5,999 | −$4,999 | −$3,995 | −$11,060 | −$11,060 | $0 | $0 | $0 | $0 | $0 |
| Acquisitions & other investing | $178,000 | $2.9M | $2.9M | −$52,001 | −$41,553 | $0 | $0 | −$999,000 | −$790,562 | −$200,517 | −$200,517 | −$513,000 |
| Cash from investing activities | $163,000 | $2.9M | $2.9M | −$57,000 | −$45,548 | −$11,060 | −$11,060 | −$999,000 | −$790,562 | −$200,517 | −$200,517 | −$513,000 |
| Financing activities | ||||||||||||
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $2.6M | $7.4M | $7.4M | $4.6M | $3.7M | −$54,510 | −$54,510 | $77,000 | $60,934 | −$29,209 | −$29,209 | −$55,000 |
| Cash from financing activities | $2.6M | $7.4M | $7.4M | $4.6M | $3.7M | −$54,510 | −$54,510 | $77,000 | $60,934 | −$29,209 | −$29,209 | −$55,000 |
| Summary | ||||||||||||
| Net change in cash | −$3.2M | $3.5M | $3.5M | $2.6M | $2.1M | −$41,870 | −$41,870 | −$5.4M | −$4.3M | −$9.1M | −$9.1M | −$8.4M |
| Cash at end of period | $4.0M | $7.3M | $7.3M | $3.7M | $3.0M | $892,711 | $892,711 | $1.2M | $936,172 | $5.2M | $5.2M | $18.1M |
| Free cash flow | −$6.0M | −$6.8M | −$6.8M | −$1.9M | −$1.5M | $304,943 | $304,943 | −$4.3M | −$3.4M | −$9.0M | −$9.0M | −$7.7M |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
TLSA cash generation
In fiscal 2025 (ended December 31, 2025), Tiziana Life Sciences generated -$12.8 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$12.9 million. Cash and equivalents rose by $0.3 million over the year.
Related: TLSA income statement, TLSA balance sheet. See the TLSA stock overview for the latest quote and news.
TLSA cash flow FAQ
What is Tiziana Life Sciences's free cash flow?
Tiziana Life Sciences's free cash flow was -$12.9 million in fiscal 2025: -$12.8 million of operating cash flow minus $0.0 million of capital expenditures It was -$1.2 million a year earlier..
How much cash does Tiziana Life Sciences generate from operations?
Tiziana Life Sciences generated -$12.8 million of cash from operating activities in fiscal 2025.
How much does Tiziana Life Sciences spend on capital expenditures?
Tiziana Life Sciences spent $0.0 million on capital expenditures in fiscal 2025, compared with $0.0 million the year before.